Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 501 to 550 of 903

TitleReference numberPublishedLast updated
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Ustekinumab for treating moderately to severely active ulcerative colitisTA633
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Larotrectinib for treating NTRK fusion-positive solid tumoursTA630
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximabTA629
Lenalidomide with rituximab for previously treated follicular lymphomaTA627
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)TA625
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisTA624
Patiromer for treating hyperkalaemiaTA623
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA617
Cannabidiol with clobazam for treating seizures associated with Dravet syndromeTA614
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndromeTA615
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pentosan polysulfate sodium for treating bladder pain syndromeTA610
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseTA607
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590
Letermovir for preventing cytomegalovirus disease after a stem cell transplantTA591
Nusinersen for treating spinal muscular atrophyTA588
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityTA589
Bisphosphonates for treating osteoporosisTA464
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormalityTA322
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576

Results per page

  1. 10
  2. 25
  3. 50
  4. All